During the recent session, Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)’s traded shares were 0.47 million, with the beta value of the company hitting 0.17. At the last check today, the stock’s price was $250.21, reflecting an intraday loss of -9.52% or -$26.34. The 52-week high for the ALNY share is $304.39, that puts it down -21.65 from that peak though still a striking 42.16% gain since the share price plummeted to a 52-week low of $144.73. The company’s market capitalization is $32.63B, and the average trade volume was 961.93K shares over the past three months.
Alnylam Pharmaceuticals Inc (ALNY) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.74. ALNY has a Sell rating from 0 analyst(s) out of 20 analysts who have looked at this stock. 4 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 16 recommend a Buy rating for it.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) trade information
Alnylam Pharmaceuticals Inc (ALNY) registered a -9.52% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -9.52% in intraday trading to $250.21, hitting a weekly high. The stock’s 5-day price performance is -1.93%, and it has moved by 11.54% in 30 days. Based on these gigs, the overall price performance for the year is 65.46%.
The consensus price target of analysts on Wall Street is $324, which implies an increase of 22.77% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $310 and $338 respectively. As a result, ALNY is trading at a discount of -35.09% off the target high and -23.9% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 23.11%. While earnings are projected to return 58.95% in 2025.
ALNY Dividends
Alnylam Pharmaceuticals Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 12.51 million shares, is of VANGUARD GROUP INC’s that is approximately 9.8694% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.04 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Alnylam Pharmaceuticals Inc (ALNY) shares are GROWTH FUND OF AMERICA and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Mar 31, 2025 indicates that GROWTH FUND OF AMERICA owns about 10.18 shares. This amounts to just over 7.81 percent of the company’s overall shares, with a $2.58 billion market value. The same data shows that the other fund manager holds slightly less at 4.04, or about 3.10% of the stock, which is worth about $1.02 billion.
